Price T Rowe Associates Inc. MD Has $4.63 Billion Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Price T Rowe Associates Inc. MD has reduced its investment in Thermo Fisher Scientific Inc. by 14.8% to approximately 9.3 million shares, making it the 25th largest position in their portfolio.
• Brokerages have varied target price adjustments for the stock, with Barclays raising it from $450 to $490, while Royal Bank of Canada decreased it from $651 to $637.
• Thermo Fisher Scientific will pay a $0.43 dividend on October 15th, which represents a 0.3% yield and a payout ratio of 9.95%.

Price T Rowe Associates Inc. MD reduced its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 14.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,304,832 shares of the medical research company's stock after selling 1,611,792 shares during the quarter. Thermo Fisher Scientific makes up approximately 0.6% of Price T Rowe Associates Inc. MD's portfolio, making the stock its 25th largest position. Price T Rowe Associates Inc. MD owned about 2.46% of Thermo Fisher Scientific worth $4,630,086,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in TMO. Brighton Jones LLC boosted its holdings in shares of Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock worth $2,293,000 after purchasing an additional 988 shares during the period. Revolve Wealth Partners LLC lifted its stake in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after acquiring an additional 20 shares during the last quarter. Bank Pictet & Cie Europe AG lifted its stake in Thermo Fisher Scientific by 0.3% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock valued at $79,677,000 after acquiring an additional 461 shares during the last quarter. First Trust Advisors LP lifted its stake in Thermo Fisher Scientific by 17.4% in the fourth quarter. First Trust Advisors LP now owns 36,602 shares of the medical research company's stock valued at $19,042,000 after acquiring an additional 5,438 shares during the last quarter. Finally, Pinebridge Investments L.P. lifted its stake in Thermo Fisher Scientific by 26.6% in the fourth quarter. Pinebridge Investments L.P. now owns 125,815 shares of the medical research company's stock valued at $65,453,000 after acquiring an additional 26,466 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 295 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $500.04, for a total transaction of $147,511.80. Following the sale, the chief executive officer owned 115,174 shares in the company, valued at $57,591,606.96. This represents a 0.26% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,896 shares of company stock worth $8,593,838 in the last quarter. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

TMO stock traded up $16.4780 on Friday, reaching $500.2380. 1,778,365 shares of the company were exchanged, compared to its average volume of 2,406,376. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The stock's fifty day moving average price is $443.02 and its 200 day moving average price is $456.60. The firm has a market capitalization of $188.89 billion, a PE ratio of 28.93, a PEG ratio of 2.67 and a beta of 0.74. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the previous year, the firm posted $5.37 earnings per share. Thermo Fisher Scientific's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's payout ratio is 9.95%.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Evercore ISI reduced their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Barclays lifted their target price on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research note on Thursday, July 24th. Argus reduced their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target on the stock in a research report on Friday, July 11th. Finally, HSBC reissued a "hold" rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $593.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.